JP Morgan Chase
PTCT icon

JP Morgan Chase’s PTC Therapeutics PTCT Stock Holding History

JP Morgan Chase’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-27,000
Closed -$1.77M – 8006
2026
Q1 		$1.77M Hold
27,000
– – ﹤0.01% 4203
2025
Q4 		$2.05M Buy
+27,000
New +$1.96M ﹤0.01% 4053
2025
Q2 		– Sell
-84,000
Closed -$4.28M – 7520
2025
Q1 		$4.28M Buy
84,000
+30,000
+56% +$1.5M ﹤0.01% 3289
2024
Q4 		$2.44M Buy
+54,000
New +$2.31M ﹤0.01% 3996
2018
Q4 		– Sell
-97,100
Closed -$4.56M – 5885
2018
Q3 		$4.56M Buy
+97,100
New +$4.02M ﹤0.01% 2811
2018
Q2 		– Sell
-45,000
Closed -$1.22M – 5660
2018
Q1 		$1.22M Sell
45,000
-115,000
-72% -$2.91M ﹤0.01% 3566
2017
Q4 		$2.67M Buy
+160,000
New +$2.71M ﹤0.01% 3138

Other funds holding PTCT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

JP Morgan Chase's PTCT Position: Q2 2026 in Review

JP Morgan Chase increased its PTC Therapeutics (PTCT) stake by 98% in Q2 2026, buying an estimated $24.4M and bringing the position to 684,042 shares worth $56.1M. The position accounts for ﹤0.01% of the portfolio, ranked #1389.

JP Morgan Chase first reported a position in PTCT in Q3 2014 and has held it in 45 quarters since. 382 funds tracked by Wall St. Rank hold PTCT as of Q2 2026.

  • JP Morgan Chase held 684,042 shares of PTC Therapeutics worth $56.1M as of Q2 2026.
  • JP Morgan Chase bought 338,025 PTC Therapeutics shares in Q2 2026, an estimated $24.4M.
  • PTC Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #1389 holding.
  • JP Morgan Chase first reported a position in PTC Therapeutics in Q3 2014 and has held it in 45 quarters since.
  • 382 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.